• Thumbnail for Venetoclax
    Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic...
    27 KB (2,575 words) - 07:01, 24 November 2024
  • Thumbnail for Bcl-2
    selective inhibitor venetoclax (ABT-199), which inhibits Bcl-2, but not Bcl-xL or Bcl-w. Clinical trials studied the effects of venetoclax, a BH3-mimetic drug...
    41 KB (4,567 words) - 08:34, 30 December 2024
  • Thumbnail for Azacitidine
    juvenile myelomonocytic leukemia. The combination of azacitidine and venetoclax is also approved for AML. Azacitidine is a chemical analogue of the nucleoside...
    20 KB (1,914 words) - 10:01, 21 December 2024
  • Thumbnail for Chronic lymphocytic leukemia
    the aim of not harming normal cells. Targeted drugs used in CLL include venetoclax (a Bcl-2 inhibitor), ibrutinib and acalabrutinib (Bruton's tyrosine kinase...
    73 KB (7,597 words) - 22:02, 28 August 2024
  • Thumbnail for Sonrotoclax
    variant, which limits the effectiveness of first-generation inhibitors like venetoclax. "Sonrotoclax - BeiGene". AdisInsight. Springer Nature Switzerland AG...
    4 KB (102 words) - 23:06, 25 November 2024
  • Thumbnail for Blastic plasmacytoid dendritic cell neoplasm
    to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in...
    22 KB (2,648 words) - 06:47, 21 June 2024
  • Thumbnail for Targeted therapy
    tofacitinib ALK inhibitors, e.g. crizotinib Bcl-2 inhibitors (e.g. FDA approved venetoclax, obatoclax in clinical trials, navitoclax, and gossypol. PARP inhibitors...
    20 KB (2,234 words) - 01:21, 22 July 2024
  • Thumbnail for Diffuse large B-cell lymphoma
    (i.e. DH/THL). RO6870810, another BET inhibitor, in combination with Venetoclax, an inhibitor of the Bcl-2 protein, is likewise in a phase I clinical...
    69 KB (8,143 words) - 23:37, 9 November 2024
  • Thumbnail for Multiple myeloma
    about 15-20% of multiple myeloma patients) may particularly benefit from Venetoclax therapy (which is FDA approved for other blood cancers but not yet available...
    131 KB (13,509 words) - 06:14, 3 December 2024
  • biomarker Senotherapy Sirtuin-activating compound Unity Biotechnology Venetoclax YPEL3 § Cellular senescence Childs BG, Durik M, Baker DJ, van Deursen...
    26 KB (2,027 words) - 18:28, 24 December 2024
  • Thumbnail for Tretinoin
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    31 KB (2,913 words) - 23:49, 9 December 2024
  • Thumbnail for Neutropenia
    Penicillamine Trimethoprim/sulfamethoxazole Clozapine Valproate Vaccination Venetoclax Severe bacterial infections, especially in people with underlying hematological...
    33 KB (3,347 words) - 17:44, 23 December 2024
  • Thumbnail for Methotrexate
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    41 KB (3,764 words) - 13:54, 13 December 2024
  • Thumbnail for Cytarabine
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    19 KB (1,757 words) - 09:15, 29 October 2024
  • Thumbnail for Hydroxycarbamide
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    20 KB (1,870 words) - 19:10, 15 December 2024
  • used to treat DLBCL-RT. Recently, small molecule anti-cancer drugs (e.g. venetoclax, atezolizumab, duvelisib, ublituximab, zanubrutinib, obinutuzumab, olatuzumab...
    37 KB (4,783 words) - 14:57, 23 February 2024
  • Thumbnail for Navitoclax
    (paclitaxel, docetaxel, gemcitabine, and irinotecan), olaparib, erlotinib, venetoclax, and rituximab in advanced hematological malignancies (in both pediatric...
    13 KB (1,295 words) - 07:06, 24 November 2024
  • remissions through fixed-duration treatment regimens in combination with venetoclax.[non-primary source needed] It is also used in combination with bendamustine...
    18 KB (1,538 words) - 03:06, 3 December 2024
  • Thumbnail for Eflornithine
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    38 KB (3,966 words) - 22:31, 11 November 2024
  • Thumbnail for Celecoxib
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    61 KB (6,093 words) - 19:43, 7 December 2024
  • (alectinib): Treatment for non-small cell lung cancer (NSCLC). 2016: Venclexta (venetoclax): Treatment for patients with chronic lymphocytic leukemia (CLL) who have...
    32 KB (2,876 words) - 17:09, 2 January 2025
  • the compound was assigned the international nonproprietary name (INN) venetoclax. Similarly, other compounds may be given a USAN or BAN for example. Finally...
    18 KB (1,675 words) - 19:23, 26 November 2024
  • mepesuccinate L01XX41 Eribulin L01XX44 Aflibercept L01XX46 Olaparib L01XX52 Venetoclax L01XX53 Vosaroxin L01XX57 Plitidepsin L01XX58 Epacadostat L01XX66 Selinexor...
    13 KB (935 words) - 04:36, 23 December 2024
  • Thumbnail for Acylsulfonamide
    Simeprevir Sulfacetamide Sulfadicramide Sulfisoxazole acetyl Vaniprevir Venetoclax Voxilaprevir Zafirlukast Several investigational new drugs contain also...
    3 KB (262 words) - 16:28, 19 December 2024
  • Nintedanib Odronextamab Pazopanib Pexidartinib Quizartinib Regorafenib Ripretinib Sorafenib Sunitinib Tebentafusp Tepotinib Tunlametinib Vandetanib Venetoclax...
    12 KB (821 words) - 06:14, 23 December 2024
  • Thumbnail for Vatalanib
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    7 KB (564 words) - 16:04, 9 January 2024
  • Thumbnail for Cancer immunotherapy
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    92 KB (12,540 words) - 18:53, 23 December 2024
  • Thumbnail for Tigilanol tiglate
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    9 KB (613 words) - 05:31, 18 July 2024
  • Thumbnail for Alkylating antineoplastic agent
    Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    13 KB (1,449 words) - 12:45, 21 August 2024
  • Talimogene laherparepvec Tazemetostat Tebentafusp Tiazofurine Tigilanol tiglate Tisagenlecleucel Trabectedin Veliparib Venetoclax Verdinexor Vosaroxin...
    34 KB (3,077 words) - 05:23, 27 December 2024